Omeros Corporation Stock price

Equities

OMER

US6821431029

Pharmaceuticals

Market Closed - Nasdaq 04:30:01 2024-03-28 pm EDT 5-day change 1st Jan Change
3.45 USD +0.88% Intraday chart for Omeros Corporation -5.99% +5.50%
Sales 2023 * - Sales 2024 * 6M Capitalization 215M
Net income 2023 * -147M Net income 2024 * -138M EV / Sales 2023 * -
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 * 35.8 x
P/E ratio 2023 *
-1.5 x
P/E ratio 2024 *
-1.92 x
Employees 196
Yield 2023 *
-
Yield 2024 *
-
Free-Float 95.96%
More Fundamentals * Assessed data
Dynamic Chart
1 day-1.16%
1 week-9.28%
Current month-24.00%
1 month-24.00%
3 months+4.91%
6 months+20.00%
Current year+4.59%
More quotes
1 week
3.34
Extreme 3.3402
3.65
1 month
3.34
Extreme 3.3402
4.85
Current year
2.76
Extreme 2.76
5.14
1 year
0.92
Extreme 0.92
7.80
3 years
0.92
Extreme 0.92
19.39
5 years
0.92
Extreme 0.92
25.46
10 years
0.92
Extreme 0.92
30.23
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 94-06-15
Director of Finance/CFO 65 13-07-31
Chief Tech/Sci/R&D Officer 63 23-10-18
Members of the board TitleAgeSince
Director/Board Member 76 12-09-26
Director/Board Member 85 01-02-28
Director/Board Member 84 94-12-31
More insiders
Date Price Change Volume
24-03-28 3.45 +0.88% 331 192
24-03-27 3.42 -1.16% 238,020
24-03-26 3.46 +0.58% 192,595
24-03-25 3.44 +1.18% 281,230
24-03-22 3.4 -7.36% 396,978

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Omeros Corporation is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor narsoplimab targets the lectin pathway of complement and is the subject of a biologics license application for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Narsoplimab is also in multiple late-stage clinical development programs focused on other complement-mediated disorders, including IgA nephropathy, COVID-19, and atypical hemolytic uremic syndrome. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria, complement 3 (C3) glomerulopathy and one or more related indications.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
2
Last Close Price
3.42
Average target price
-
Consensus
  1. Stock
  2. Equities
  3. Stock Omeros Corporation - Nasdaq